Related Experiment Video
Updated: Jan 16, 2026
09:51
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
13.0K
Toll-Like Receptor 7/8 Antagonist Promotes Interleukin-10-Mediated Anti-inflammatory Therapy
Grahmm A Funk1, Jin Xie1, Tamara A Kucaba2
1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.
ACS Pharmacology & Translational Science
|January 15, 2026
Summary
A novel Toll-like receptor (TLR) 7/8 antagonist, 621, effectively suppresses inflammation by promoting anti-inflammatory cytokines and immunosuppressive cells. This compound shows promise as a new therapy for inflammatory diseases.
Area of Science:
- Immunology
- Pharmacology
Background:
- Toll-like receptors (TLR) 7 and 8 are crucial pattern recognition receptors involved in immune responses to pathogens.
- Activation of TLR7/8 by agonists promotes inflammation, while their antagonism's effects remain largely unexplored.
Purpose of the Study:
- To investigate the immunosuppressive potential of a novel TLR7/8 antagonist, designated 621.
- To elucidate the immune mechanisms underlying the action of TLR7/8 antagonism.
Main Methods:
- In vitro studies using mouse dendritic cell (DC) assays.
- In vivo studies in mouse models, including systemic administration and a DSS-colitis model.
- Comparative analysis with a TLR7/8 agonist (558) and challenge with TLR4 agonist (LPS) or resiquimod (RESQ).
Main Results:
- 621 induced anti-inflammatory IL-10 production in DCs without promoting pro-inflammatory TNF.
- Systemic 621 administration increased serum IL-10 and decreased TNF in mice.
- 621 treatment increased regulatory T cells (Tregs) and M2 macrophages and mitigated DSS-colitis.
Conclusions:
- The novel TLR7/8 antagonist 621 exhibits significant anti-inflammatory and immunosuppressive properties.
- 621 promotes a shift towards an anti-inflammatory immune phenotype.
- This compound represents a potential novel therapeutic agent for inflammatory diseases.
Related Concept Videos
01:24T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
01:28Inflammatory Response
16.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
16.0K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
490
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
490
01:20The JAK-STAT Signaling Pathway
12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.0K
01:16TGF - β Signaling Pathway
10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K